Osteoarthritis News and Research

Latest Osteoarthritis News and Research

Artimplant reports net revenue of SEK 9.7 million for January – June, 2011

Artimplant: First six months: Net revenue amounted to SEK 9.7 million.

3 Aug 2011

AstraZeneca recruits patients for KODIAC Phase III trial in opioid-induced constipation

AstraZeneca today announced that study centers across the U.S. are recruiting patients for a clinical study to examine whether an investigational drug is safe and effective in treating opioid-induced constipation.

2 Aug 2011

RSS honors UNC researcher with 2011 Distinguished Service to Rural Life Award

Joanne M. Jordan, MD, MPH, director of the Thurston Arthritis Research Center at the University of North Carolina at Chapel Hill, has received the 2011 Distinguished Service to Rural Life Award from the Rural Sociological Society.

2 Aug 2011

Heart disease remains most costly condition in terms of health care expenditure for women: AHRQ

The cost of treating women for heart disease in 2008 was $43.6 billion, leading a list of the top 10 most expensive conditions for women, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

30 Jul 2011

Positive data from Histogenics' NeoCart Phase 2 study on knee cartilage injury

Histogenics Corporation, a privately held regenerative medicine company, today announced the presentation of positive Phase 2 data for the NeoCart Autologous Cartilage Tissue Implant.

29 Jul 2011

POZEN reports revenue of $4.6 million for second quarter 2011

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2011.

28 Jul 2011

High rates of osteoarthritis in athletes linked to femur damage during adolescence

New study links high rates of osteoarthritis in athletes to femur damage during adolescence, as a result of participation in high-intensity sports.

20 Jul 2011

Valeant, sanofi-aventis partner to market and distribute Zuacta cream

Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Valeant International SRL, has entered into an agreement with sanofi-aventis Canada Inc.

20 Jul 2011

Symposium to raise awareness and increase knowledge of OA among nurses

Osteoarthritis is a leading cause of disability in the United States, affecting 27 million Americans. In an effort to raise awareness and increase knowledge of OA among the nursing community, Hospital for Special Surgery, the American Journal of Nursing and the National Association of Orthopaedic Nurses will present a groundbreaking two-day symposium: "State-of-the-Science in the Prevention and Management of Osteoarthritis" on Thursday, July 14, and Friday, July 15.

13 Jul 2011

Arthroscopy as effective as open surgery for patients with common hip problem

Researchers at Hospital for Special Surgery have found that in comparison to open surgery, arthroscopic treatment of a common hip problem that leads to arthritis produces similar outcomes in terms of repairing structural problems in most patients.

11 Jul 2011

Patients with motion limitations after knee surgery more likely to develop osteoarthritis

The onset of osteoarthritis may be related to a loss of knee motion after reconstructive ACL surgery, as noted in new research presented at the American Orthopaedic Society for Sports Medicine's Annual Meeting in San Diego, California, July 7-10, 2011.

11 Jul 2011

Arthroscopy restores range of motion in patients with common hip problem

Arthroscopic treatment of a common hip problem that leads to arthritis is successful in terms of restoring range of motion, according to results from a recent Hospital for Special Surgery study.

11 Jul 2011

High BMI and vigorous physical activity increase risk of arthroplasty in men

Surprising results from a new study revealed that men who smoke had less risk of undergoing total joint replacement surgery than those who never smoked.

8 Jul 2011

Gender may increase risk of cartilage lesions in ACL knee injury

Gender may be associated with an increased risk of cartilage lesions in anterior cruciate ligament (ACL) injured knees, according to research being presented at the American Orthopaedic Society for Sports Medicine's Annual Meeting in San Diego.

7 Jul 2011

AHRQ and Ad Council announce new campaign, 'Explore Your Treatment Options'

"Explore Your Treatment Options," a new multimedia ad campaign announced today by the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality and the Ad Council, encourages patients to become more informed about their options before choosing a treatment for a health condition or illness.

1 Jul 2011

Study links foot positioning during running and walking with risk of ankle sprains

The position of the foot just before ground contact during running and walking may put people at risk for ankle sprains, according to a new study published by a University of Georgia kinesiology researcher.

1 Jul 2011

PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced receipt from Mallinckrodt Inc., a Covidien company (Covidien), of top-line results from a Phase 2 study conducted by Covidien, of twice-daily administration of PENNSAID Viscous Solution (topical diclofenac sodium viscous solution) 2% w/w, previously referred to as PENNSAID Gel.

30 Jun 2011

Incidence of osteoarthritis more prevalent among military populations

New research shows significantly higher osteoarthritis (OA) incidence rates in military populations than among comparable age groups in the general population.

30 Jun 2011

Zalicus commences Synavive SYNERGY Phase 2b clinical trial for rheumatoid arthritis

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of the SYNERGY trial, a Phase 2b clinical trial evaluating Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).

29 Jun 2011

FDA clears Nuvo's IND for Lidocaine Spray formulation

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application filed May 27, 2011 for a novel topical Lidocaine Spray formulation (NRI-ANA), allowing for initiation of Phase 1 studies.

29 Jun 2011